The global biopharmaceutical CMO and CRO market is estimated to be valued at US$ 36.2 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Biopharmaceutical contract manufacturing and contract research organizations help pharmaceutical and biotech companies conduct preclinical and clinical stage drug development, clinical trials, and new drug applications by providing drug development and manufacturing services. This enables biopharma companies to focus on drug discovery while outsourcing other development functions.
Market key trends:
Outsourcing to contract research organizations (CROs) and contract manufacturing organizations (CMOs) has become a prominent trend in the biopharmaceutical industry over the past few years. Biopharma companies are increasingly relying on CROs and CMOs to conduct clinical trials, develop manufacturing processes, produce biologic drug substances and products, and handle other drug development functions. This allows biopharma firms to reduce fixed costs and focus internal resources on core drug discovery and early development activities. The outsourcing of non-core functions to specialized service providers also helps accelerate development timelines and brings expertise that many biopharma companies may lack in-house. This rising reliance on outsourcing is expected to continue driving demand for CRO and CMO services over the forecast period.
SWOT Analysis
Strength: The biopharmaceutical CMO and CRO market provides specialized services to biopharmaceutical companies. This allows biopharmaceutical companies to focus on drug development while outsourcing manufacturing and clinical trial needs.
Weakness: Regulatory processes in biopharmaceutical contract manufacturing and clinical research are complex which increases costs and timeline for CMOs and CROs. Intellectual property related risks also exist.
Opportunity: Increasing R&D expenditure of biopharmaceutical companies and growing clinical trial activities globally present significant growth opportunities. Advancements in technologies like AI/ML also offer opportunities for innovating services.
Threats: Pricing pressures from clients, intense competition, and consolidation in the industry pose major threats. Delays in clinical trials and regulatory approvals can also impact financial performance.
Key Takeaways
The Global Biopharmaceutical CMO and CRO market size is expected to witness high growth over the forecast period driven by increasing demand for outsourcing and advancements in technologies.
Regional analysis: North America dominates the market currently owing to presence of major players and higher clinical trial activities in the US. However, Asia Pacific is expected to grow at the fastest pace due to lower costs and expanding biopharma industry in countries like China and India.
Key players: Key players operating in the biopharmaceutical CMO and CRO market are Allphase Clinical Research, AlcheraBio, Alcami, Akos Urgent Care, Agilent, AGC Biologics, Affinity Life Sciences, Inc., Actimus Bio, ACI Clinical, Accumedix, Inc., Absorption Systems, A10 Clinical Solutions, Albuquerque Clinical Trials (ACT), Ajinomoto Bio-Pharma Services, Advanced Clinical Services LLC, ACM Global Laboratories, Accelerated Enrollment Solutions, AbbVie Contract Manufacturing, Advanced BioScience Laboratories, Advanced Clinical Research Institute, and Alliance for Clinical Trials in Oncology, among others. They are focusing on expanding their service portfolio and global footprint through organic and inorganic growth strategies.